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OUTCOMES FOLLOWING HEART TRANSPLANTATION IN A NATIONAL COHORT: AN 
ANALYSIS OF THE ORGAN PROCUREMENT AND TRANSPLANTATION NETWORK’S 
DATABASE. Oliver K. Jawitz, Pramod N. Bonde. Section of Cardiac Surgery, Department of Surgery, 
Yale University, School of Medicine, New Haven, CT. 
 
Abstract 
In this analysis, we examine a large national cohort within the Organ Procurement and Transplantation 
Network’s (OPTN) United Network for Organ Sharing (UNOS) database for the purpose of determining 
the impact of a recipient history of myocarditis as well as donor/recipient ABO compatibility on outcomes 
following heart transplantation. We used a nationwide sample with primary stratification between ABO 
identical and compatible heart transplantations or transplant recipients diagnosed with myocarditis and 
those diagnosed with ischemic or idiopathic cardiomyopathy. The primary end-point was graft failure from 
all causes. Post-transplant survival was compared between groups using univariate Kaplan-Meier as well as 
multivariate Cox proportional hazard and logistic regression models. ABO compatible recipients were 
generally sicker than ABO identical recipients before transplant as a larger proportion were Status 1A, in 
the ICU, and on mechanical ventilatory support (p < 0.05). Multivariate analysis did not demonstrate 
adverse outcomes associated with ABO compatible transplants in terms of decreased graft survival (hazard 
ratio 0.99, p = 0.87). Blood type O donor grafts, however, were associated with poorer outcomes compared 
with all other types (p < 0.05), which has important implications for current graft allocation policies. For 
recipients with a history of myocarditis, survival was comparable with ischemic or idiopathic 
cardiomyopathy. Patients with myocarditis were more likely to be female, younger, in the ICU before 
transplant, and on ECMO, ventilatory support, and VAD pre-transplant (p < 0.05). Transplant recipients 
diagnosed with myocarditis were more likely to die from acute (p < 0.05) and chronic graft failure (p < 
0.05). Strategies to safely bridge these patients to transplant such as mechanical circulatory support should 
be considered earlier in the disease. Furthermore, this analysis suggests that post-transplant outcomes 
of patients with a history of myocarditis could be improved with more intensive 
immunosuppression. 
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INTRODUCTION 
Cardiac transplantation is widely considered the gold-standard therapy for treating 
patients with end-stage heart failure refractory to medical management. Absolute 
indications for cardiac transplantation from the ACC/AHA include hemodynamic 
compromise due to heart failure including refractory cardiogenic shock, dependence on 
IV inotropes, and peak oxygen consumption less than 10mL per kg per minute with 
anaerobic metabolism. Other absolute indications include severe debilitating ischemia not 
amenable to coronary artery bypass surgery or percutaneous coronary intervention as 
well as recurrent symptomatic ventricular arrhythmias refractory to all other therapies [1].  
Outcomes following heart transplantation have improved significantly since 
Christiaan Barnard performed the first human-to-human heart transplantation in 1967. 
The most significant scientific breakthrough regarding the management of post-heart 
transplant recipients was the introduction of cyclosporine-based immunosuppression 
regimens in the early 1980’s [2]. Since this time, post-transplantation survival has 
continued to improve with further advances in immunosuppression, more careful 
selection of donors and recipients, as well as the development of more efficacious 
approaches to preventing and treating infection. Despite the tremendous advances made 
in the past several decades, of the approximately 2,000 procedures performed in the 
United States annually, about 10% of patients do not survive the first year post transplant 
[3]. After one year, annual death rates approach 4% and approximately 50% of heart 
transplant recipients are alive at 10 years [4].  
The purpose of this thesis is to analyze outcomes following heart transplantation 
using the United Network for Organ Sharing (UNOS) heart transplantation database in 
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order to identify potential areas of improvement in national organ allocation policies as 
well as donor and recipient selection strategies. In doing so, the use of the limited supply 
of donor organs in this country could be made more efficient, thus improving outcomes 
for potential heart transplant recipients and maximizing the benefit of this limited donor 
pool. The thesis will be divided into two parts: (1) an analysis of outcomes following 
heart transplantation for recipients with a history of myocarditis and (2) an analysis of the 
impact of ABO blood type compatibility on heart transplant outcomes. Both are areas of 
contention with conflicting evidence presented in the medical literature and both have 
important implications for optimal organ allocation. This study was deemed exempt by 
the Yale University’s Institutional Review Board. 
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Part 1 
Heart transplantation for myocarditis: outcomes and survival in a national cohort 
 
BACKGROUND 
Myocarditis, defined as an inflammatory disease of the myocardium, has a wide 
range of clinical manifestations and is often the result of infectious and toxic agents as 
well as hypersensitivity reactions [5]. While the natural history of myocarditis is variable, 
dilated cardiomyopathy (DCM) is often the result. DCM is the most frequent indication 
for heart transplantation and is usually considered following the failure of maximal 
medical management. Between 2006 and 2012, approximately 54% of all heart 
transplants performed worldwide were for dilated cardiomyopathy [6].  
 Before considering transplantation, there are a number of medical treatment 
options available for acute and chronic myocarditis. Pharmacologic treatment focused on 
the specific etiology of myocarditis is generally considered to be the optimal management 
strategy. For example, treatment of giant cell myocarditis and cardiac sarcoidosis usually 
involves immunosuppression. In addition, due to the very high incidence of systolic 
dysfunction in patients with myocarditis, standard heart failure therapy is also a 
requirement. This therapy should be administered in accordance with the patient’s New 
York Heart Association (NYHA) functional class and typically involves beta-blockers, 
diuretics, angiotensin-converting enzyme (ACE) inhibitors or angiotensin-II receptor 
blockers (ARBs) [7]. In patients with advanced heart failure refractory to maximal 
pharmacologic therapy, mechanical circulatory support is utilized, including ventricular 
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assist devices (VAD) or extracorporeal membrane oxygenation (ECMO), as a bridge to 
recovery or cardiac transplantation [8-11]. 
 Due to the relative paucity of published data investigating post-transplantation 
outcomes of recipients with a history of myocarditis and chronic inflammatory 
cardiomyopathy, controversy still exists regarding the optimal use of transplantation in 
this heterogeneous patient population [12]. Several small, single-center studies published 
in the early 1990’s suggested decreased post-transplant survival as well as increased rates 
of rejection in these patients compared with the general population [13,14]. Since this 
time, a number of studies utilizing both single-center and national cohorts have 
demonstrated varying rates of acute and chronic rejection but equivalent post-transplant 
survival in patients with myocarditis compared with other recipients [15-17]. 
 The purpose of this study is to characterize the cohort of patients that have 
undergone heart transplantation for myocarditis in the United States over the past several 
decades and compare the post-transplant outcomes of these patients to recipients with the 
most common pre-transplant diagnoses: ischemic and idiopathic dilated cardiomyopathy. 
It is hypothesized that given the substantial differences between the pathophysiology of 
these more common conditions with that of end-stage myocarditis requiring orthotopic 
heart transplantation, the baseline characteristics of these recipients will be quite 
dissimilar. As a result, post-transplantation outcomes between these two cohorts are 
likely quite dissimilar as well. The data gleaned from this study will be invaluable for 
clinical decision-making involving patients with myocarditis who have failed standard 
pharmacologic heart failure therapy and mechanical circulatory support.  
 
	   5	  
METHODS 
 The United Network for Organ Sharing (UNOS) provided Standard Transplant 
Analysis and Research (STAR) files with de-identified donor and recipient transplant 
data from October 1987 to March 2013 and recipient follow-up data through December 
2012. The database includes prospectively collected demographic, donor, operative, and 
postoperative information for all thoracic transplant recipients in the United States.  
 
Study Design 
We retrospectively reviewed the UNOS database from October 1987 to March 
2013. The time-points were chosen to maximize the study period thereby capturing as 
many patients as possible that fit within the inclusion criteria. All single-organ heart 
transplants with a primary recipient diagnosis of idiopathic or ischemic dilated 
cardiomyopathy as well as biopsy-proven myocarditis were included. Transplants were 
primarily stratified by recipient diagnosis (idiopathic and ischemic DCM vs. 
myocarditis).  
 
Outcome Measures 
Demographic and clinical characteristics of all heart transplant donors and 
recipients were examined. This includes donor and recipient age, gender, ethnicity, and 
medical history as well as donor cause of death and recipient waitlist status and location 
before transplant. The primary end-point was all-cause mortality during the study period. 
Secondary outcomes of interest included 30-day mortality, length of hospital stay, graft 
rejection, as well as recipient cause of death. 
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Statistical Analysis 
Baseline demographic and clinical characteristics between the primary study 
cohorts were compared using Student’s t-test for continuous variables and the chi-square 
test for categorical variables. Survival was modeled using the Kaplan-Meier method with 
statistical differences between survival curves assessed using the log-rank (Mantel-Cox) 
test. Univariate, unadjusted 30-day, 1-year, 3-year, 5-year, and 10-year graft survival 
analyses were also conducted using the chi-square test. Multivariate analysis was 
conducted using the Cox proportional hazards regression model. In order to adjust for 
potential confounders and accurately determine factors associated with decreased post-
transplant survival, variables describing baseline demographic and clinical characteristics 
that were significantly different (p < 0.05) between the two study cohorts on univariate 
analysis were included in the multivariate model.  
Statistical significance was established at p < 0.05 (2-tailed) and all hazard ratios 
are presented with 95% confidence intervals. All statistical analysis was generated using 
SAS software, Version 9.3 of the SAS System for Windows. (©SAS Institute Inc., Cary, 
NC, USA). Oliver Jawitz performed all statistical analyses. 
 
RESULTS 
 The UNOS database contained records of 554 heart transplants for patients with 
biopsy-proven myocarditis and 32,337 transplants for ischemic and idiopathic dilated 
cardiomyopathy during the study period that fit the inclusion criteria. The baseline 
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demographic characteristics of both donors and recipients from these transplant surgeries 
are summarized in Tables 1 and 2, respectively. 
 
 
 
The allograft donors from both cohorts were well matched based on ethnicity, 
history of hypertension, diabetes, and cancer, as well as mean left ventricular ejection 
fraction (LVEF). There was a significant difference (p < 0.05) between the two groups in 
terms of donor gender, age, history of cigarette use, and cause of death. Compared with 
transplants for ischemic/idiopathic dilated cardiomyopathy, donors for patients with 
myocarditis were more frequently female (35.2% vs. 29.0%), younger (mean age 23.6 vs. 
29.8 years), and had a cause of death listed as anoxia (13.6% vs. 10.25). These donors 
less frequently had a history of cigarette use (15.8% vs. 26.5%) and had a primary cause 
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of death listed as cerebrovascular/stroke (19.4% vs. 25.0%) or head trauma (50.9% vs. 
56.8%). 
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The baseline demographic and clinical characteristics of heart recipients in the 
myocarditis and ischemic/idiopathic DCM cohorts differed (p < 0.05) with respect to 
gender, age, ethnicity, location before transplant (intensive care unit vs. outside hospital), 
waitlist status, history of cardiac surgery, diabetes, cigarette use, use of life support, IV 
antibiotics, chronic steroids, as well as mean serum creatinine and cytomegalovirus 
(CMV) immunoglobulin G (IgG) status before transplant. Recipients with myocarditis 
were more often female (41.5% vs 22.6%), younger (mean age 30.0 vs. 50.1 years), 
African American (21.4% vs. 16.3%), waitlist status 1A and 1B (83.8% vs. 76.1%), in the 
ICU at transplant (58.3% vs. 39.7%), and on ECMO (6.7% vs. 0.5%), ventilator (13.4% 
vs. 3.2%), and VAD (25.6% vs. 19.4%) support. They also more frequently had a history 
of IV antibiotic use in the two weeks prior to transplant (20.1% vs. 11.0%), chronic 
steroid use (14.0% vs. 7.5%) and were more often CMV IgG positive (74.4% vs. 35.3%). 
Compared to recipients with ischemic or idiopathic dilated cardiomyopathy, recipients 
with myocarditis were less frequently white (67.0% vs. 73.9%), on IV inotropes (36.6% 
vs. 43.0%), had a history of cardiac surgery (5.2% vs. 13.4%), diabetes (3.8% vs. 18.8%), 
and cigarette use (5.4% vs. 18.0%), and had lower mean serum creatinine at transplant 
(1.02 vs. 1.35 mg/dL). The two study cohorts were well matched based upon ABO blood 
type, history of dialysis, mean ischemic time, and pre-transplant overall, class I, and class 
II panel reactive antibody (PRA). 
Table 3 shows unadjusted 30 day, 1 year, 3 year, 5 year, and 10 year post-
transplant survival for heart transplant recipients with a history of myocarditis as well as 
ischemic and idiopathic dilated cardiomyopathy. Survival rates were equivalent (p > 
0.05) for both cohorts at all time points. In addition, there was no difference in the 
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incidence of rejection between transplant and discharge (p = 0.16) and mean length of 
stay, transplant to discharge (p = 0.93). 
 
Recipient cause of death differed significantly (p < 0.05) between the two cohorts 
in terms of death from graft failure as well as infection (Table 4). Recipients with a 
history of myocarditis more frequently died from graft failure (30.5% vs. 18.3%), 
including acute rejection (11.7% vs. 6.7%) and chronic rejection (12.7% vs. 3.5%). In 
addition, compared with recipients with a history of ischemic or idiopathic dilated 
cardiomyopathy, those diagnosed with myocarditis less frequently died from infection 
(9.1% vs. 16.0%). 
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When post-transplant survival was compared between the two study cohorts using 
the Kaplan-Meier method (Figure 1), recipients with a diagnosis of biopsy-proven 
myocarditis as well as those with ischemic/idiopathic dilated cardiomyopathy were 
equivalent as demonstrated by the log-rank test (p = 0.42). 
  
Figure 1. Kaplan-Meier transplant recipient survival analysis, myocarditis vs. ischemic and 
idiopathic dilated cardiomyopathy (dashed line: myocarditis, solid line: ischemic and idiopathic 
dilated cardiomyopathy). A table is given with the number of patients at risk at each time point. 
The p-value corresponds to Mantel-Cox log-rank test results. 
 
The multivariate Cox proportional hazards regression model (Table 5) indicated 
several variables as independent predictors of increased post-transplant mortality (p < 
0.05). These include donor and recipient age, recipient ethnicity, use of ECMO, 
ventilatory support, and VAD at transplant, recipient location before transplant (in the 
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ICU), recipient serum creatinine, history of prior cardiac surgery, diabetes, and IV 
antibiotics in the prior two weeks, as well as donor and recipient cigarette use. 
Importantly, recipient diagnosis of myocarditis, compared with ischemic/idiopathic 
DCM, was not a significant independent predictor of mortality (hazard ratio [recipient 
diagnosis – myocarditis] 1.05, p = 0.64). 
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DISCUSSION 
 This study represents the largest investigation of post-heart transplant outcomes in 
patients with myocarditis to date. A large, diverse cohort of patients was used spanning 
several decades of heart transplantation in the United States.  
 Due to the fact that heart transplant donors and recipients are frequently matched 
based on many factors including age, size, and gender, the differences in baseline 
characteristics between myocarditis and ischemic/idiopathic DCM transplant donors, 
especially with regard to age and gender, are likely the direct result of corresponding 
differences between recipients.  
 Compared with the most common indications for heart transplant, ischemic and 
idiopathic dilated cardiomyopathy, organ recipients with a history of myocarditis induced 
dilated cardiomyopathy had equivalent outcomes in terms of survival, length of hospital 
stay, and incidence of hyperacute graft rejection. Considering the substantial 
demographic disparities between the two cohorts pre-transplant, these results are 
somewhat surprising. The myocarditis patients were more likely to be female, younger, 
and have less comorbidity than recipients with a history of ischemic or idiopathic dilated 
cardiomyopathy and might therefore be expected to have increased survival post-
transplant.  
While actual post-transplant survival was identical between the two cohorts, 
specific causes of death were quite different. Patients with a history of myocarditis had 
significantly higher rates of death from primary graft failure including acute and chronic 
rejection and less frequently died from infection. This is likely the result of significant 
disparities between the two cohorts in terms of baseline demographic characteristics. 
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Furthermore, these findings suggest that recipients with a history of myocarditis induced 
dilated cardiomyopathy might benefit from increased immunosuppression post-
transplant. Recent advances in post-transplant immunosuppression regimens have 
significantly decreased rates of rejection and have therefore certainly helped improve 
these patients’ prognosis [5,18].  It should be noted, however, that analysis of a more 
recent cohort of patients demonstrated similar findings in terms of recipient survival and 
cause of death. 
 
CONCLUSIONS 
 The favorable post-transplant survival rate of patients with a history of 
myocarditis suggests that those patients with myocarditis induced end-stage heart failure 
should be aggressively treated and bridged to transplant using mechanical circulatory 
support modalities IABP and VAD. In addition, the post-transplant survival of these 
patients could be improved with a more intensive immunosuppression regimen that is 
specifically tailored to the inflammatory nature of their primary disease. 
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Part 2 
Impact of ABO compatibility on outcomes following heart transplantation in a 
national cohort over the last decade. 
 
BACKGROUND 
There are several risk factors known to be associated with premature death and 
other complications following cardiac transplantation including donor cardiac function 
and preexisting disease, toxicity, systemic infection, ischemic time, as well as 
mismatches between donor and recipient heart size, gender, age, and antigenic 
phenotypes [19]. Since basic immunological incompatibility is a clear indication for post-
transplant complications, it is common practice to avoid antigenic mismatch when pairing 
donor hearts with recipients. Human leukocyte antigen (HLA) matching is currently 
applied only to highly sensitized individuals listed for heart transplantation, although 
many centers are now using a strategy of “virtual” cross-matching [20]. Organ donors 
and potential recipients are, however, paired based upon ABO blood type matching. 
There are three categories of ABO matching: ABO identical, ABO compatible, and ABO 
incompatible. While adult patients typically do not receive organs from ABO 
incompatible donors, avoiding hyperacute graft rejection, recipients sometimes receive 
hearts from ABO compatible donors. This is unlike transplant procedures for pediatric 
recipients, where ABO incompatible grafts are sometimes acceptable due to a delay in the 
development of natural antibodies to ABO antigens [21].  
Morbidity and mortality associated with recent increases in donor shortages for all 
organ transplantation types has led to a renewed interest in ABO-incompatible matching. 
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While significant progress has been made on this front in the fields of kidney and 
pediatric heart transplantation, ABO compatibility is largely still a requirement for adult 
heart transplantation [22]. Before ABO-incompatible adult heart transplantation can be 
considered, however, it is important to first solidify our understanding of ABO-identical 
and ABO-compatible heart transplantation. In the late 1980’s and early 1990’s, several 
anecdotal reports suggested unfavorable outcomes among ABO compatible (non-
identical) adult heart transplants [23,24]. Since then, however, a number of small, 
hospital-based retrospective studies have been conducted which have largely determined 
that there are no significant differences in outcomes of ABO compatible versus ABO 
identical cardiac transplants [24-26]. The 2012 ISHLT Heart Transplant Report listed 
non-ABO identical transplants as a borderline significant risk factor for five-year 
mortality post-transplant [27]. It is hypothesized that ABO compatible and ABO identical 
transplants are associated with similar post-transplantation survival. We believe that it 
would be clinically useful to compare the medium and long-term outcomes of ABO 
compatible and ABO identical heart transplants in a large nationwide modern cohort 
study. Data gleaned from this study could have significant implications for the maximally 
efficient usage of the limited donor pool. 
 
METHODS 
Data Source 
The United Network for Organ Sharing (UNOS) provided Standard Transplant 
Analysis and Research (STAR) files with de-identified donor and recipient transplant 
data from October 1987 to March 2012 and recipient follow-up data through December 
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2011. The database includes prospectively collected demographic, donor, operative, and 
postoperative information for all thoracic transplant recipients in the United States.  
 
Study Design 
We retrospectively reviewed the UNOS database from January 2000 to December 
2009. The time-points were chosen to identify a modern cohort of heart transplant 
patients with adequate time for follow-up. All adult (≥18 years) single-organ heart 
transplants were included. Transplants were primarily stratified by transplant donor-
recipient ABO blood type matching (identical vs. compatible). Transplants without 
available data on donor and/or recipient ABO types were excluded from the study (n=1). 
 
Outcome Measures 
Demographic and clinical characteristics of all heart transplant donors and 
recipients were examined. This included donor and recipient age, gender, ethnicity, and 
relevant medical history. Donor cause of death as well as recipient waitlist status, 
location, and life support at transplant were also analyzed. The primary end-point was all-
cause graft failure during the study period. Secondary outcomes of interest included 30-
day mortality, length of hospital stay, graft rejection, as well as recipient cause of death. 
 
Statistical Analysis 
Baseline demographic and clinical characteristics between the primary study 
cohorts were compared using Student’s t-test for continuous variables and the chi-square 
test for categorical variables. For all Student’s t-tests conducted, normality was assessed 
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using skewness and kurtosis. Survival was modeled using the Kaplan-Meier method with 
statistical differences between survival curves assessed using the log-rank (Mantel-Cox) 
test. Univariate, unadjusted 30-day, 1-year, 3-year, 5-year, and 10-year graft survival 
analyses were also conducted using the chi-square test. Multivariate analysis was 
conducted using both the Cox proportional hazards regression model as well as a logistic 
regression model. In order to adjust for potential confounders and accurately determine 
factors associated with decreased graft survival, variables describing baseline 
demographic and clinical characteristics that were significantly different (p < 0.05) 
between the two study cohorts on univariate analysis were included in the multivariate 
models. For the logistic regression analysis, variables were removed from the model in a 
stepwise fashion until all included variables (except ABO compatibility, the variable of 
interest) were statistically significant (p < 0.05). 
 Statistical significance was established at p < 0.05 (2-tailed) and all hazard ratios 
are presented with 95% confidence intervals. All statistical analysis was generated using 
SAS software, Version 9.3 of the SAS System for Windows. (©SAS Institute Inc., Cary, 
NC, USA). Oliver Jawitz performed all statistical analyses. 
 
RESULTS 
The UNOS database contained records of 15,267 ABO identical transplants and 
2,684 ABO compatible transplants during the study period from January 2000 to 
December 2009 that fit the study’s inclusion criteria (Table 6). Of the transplant 
recipients with blood types A, B, and AB, the frequency of ABO compatible transplants 
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was 17.0%, 32.8%, and 61.8%, respectively. Blood type O recipients can only receive 
ABO identical grafts. 
 
The baseline demographic characteristics of both donors and recipients from these 
transplant surgeries are summarized in Tables 7 and 8, respectively. The allograft donors 
from both cohorts were well matched based on gender, age, mean left ventricular ejection 
fraction (LVEF), cause of death, as well as a history of hypertension, diabetes, and 
cigarette use. There was a significant difference (p < 0.05) between the two groups in 
terms of donor ethnicity and history of cancer. 
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 The baseline demographic and clinical characteristics of heart recipients in the 
ABO identical and ABO compatible cohorts differed (p < 0.05) with respect to gender, 
age, ethnicity, waitlist status at transplant, status before transplant (in ICU, in hospital, or 
not hospitalized), life support before transplant, as well as mean graft ischemic time and 
total bilirubin. A larger proportion of ABO compatible transplant recipients were waitlist 
status 1A (50.3%) than ABO identical transplant recipients (28.3%, p < 0.001). 
Additionally, 40.4% of ABO compatible recipients were in the ICU prior to transplant 
compared to only 28.3% of ABO identical recipients (p < 0.05). When compared with 
ABO identical transplant recipients, ABO compatible transplant recipients were more 
frequently on life support prior to transplant (p < 0.05), including extracorporeal 
membrane oxygenation (ECMO), intra-aortic balloon pump (IABP), IV inotropes, and 
ventilator support. There was no statistical difference between the two groups in terms of 
ventricular assist device (VAD) use (p = 0.266). Graft ischemic time and total bilirubin 
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also differed between the two study cohorts (p < 0.001); ABO identical transplant 
recipients had a longer mean ischemic time and lower total bilirubin (3.23 hours, 1.25 
mg/dL) compared to ABO compatible transplant recipients (3.11 hours, 1.48 mg/dL). 
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 Table 9 shows unadjusted 30 day, 1 year, 3 year, 5 year, and 10 year graft survival 
for ABO identical and ABO compatible heart transplant recipients. Recipients of ABO 
identical grafts had increased graft survival (p < 0.05) compared to ABO compatible 
recipients at 30 days (94.4% vs. 93.3%), 1 year (87.0% vs. 84.4%), 3 years (76.3% vs. 
73.4%), and 5 years post-transplant (63.1% vs. 60.0%). There was no statistically 
significant difference in graft survival at 10 years post-transplant (p = 0.21). In addition, 
there was no difference in the incidence of rejection between transplant and discharge (p 
= 0.53) and mean length of stay, transplant to discharge (p = 0.97).  
 
 Transplant recipient cause of death was similar between ABO identical and 
compatible recipients except for mortality due to primary graft failure as well as 
malignancy (Table 10). A greater proportion of ABO compatible heart recipients died 
from primary graft failure then ABO identical recipients (8.7% vs. 5.8%, p = 0.003). 
Interestingly, ABO identical transplant recipients showed a greater incidence of death due 
to malignancy than the ABO compatible cohort (9.8% vs. 6.6%, p = 0.007). 
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 When graft survival was compared between the two study cohorts using the 
Kaplan-Meier method (Figure 2), ABO identical recipients showed a slightly higher 
degree of graft survival, although the log-rank test showed that this difference was not 
statistically significant (p = 0.09).   
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Figure 2. Kaplan-Meier graft survival analysis, ABO compatible vs. ABO identical 
transplants (solid line: ABO compatible transplants, dashed line: ABO identical 
transplants). A table is given with the number of patients at risk at each time point. The 
p-value corresponds to Mantel-Cox log-rank test results. 
 
The multivariate Cox proportional hazards regression model (Table 11) 
demonstrated six variables of significance (p < 0.05) for the outcome measure of graft 
failure: recipient ethnicity, ventilatory support at transplant, pre transplant ECMO use, 
graft ischemic time, total bilirubin, as well as patient status before transplant (in ICU, in 
hospital, or not hospitalized). While univariate analysis showed ABO blood type 
matching (identical vs. compatible) to have a significant impact on the incidence of graft 
failure, this effect was eliminated when controlling for potential confounders in the 
multivariate model (hazard ratio [ABO compatible] 0.991, p = 0.865).  
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In the multivariate logistic regression model showing risk factors for 30 day graft 
failure post-transplant, variables of significance (p < 0.05) were life support at transplant, 
including IV inotropes, ventilator support, pre transplant ECMO use; ischemic time, 
waitlist status at transplant, status before transplant (in ICU, in hospital, or not 
hospitalized), as well as total bilirubin (Table 12). Once again, when controlling for 
potential confounding variables, ABO matching (identical vs. compatible) was not 
statistically significant (p = 0.08). 
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Post-transplant graft survival was also compared among different donor ABO 
blood groups using the Kaplan-Meier method (Figure 3). This analysis demonstrated 
decreased graft survival associated with type O donors and increased survival associated 
with type A donors (p < 0.05) when compared to all other blood types. Type B and AB 
donors were not associated with either increased or decreased graft survival when 
compared with the other ABO blood types (p > 0.05). When looking at post-transplant 
graft survival in blood type B recipients (Figure 4), blood type O donor hearts were 
associated with decreased graft survival when compared with type B grafts (p < 0.05). 
	   27	  
 
Figure 3. Kaplan-Meier graft survival analysis, donor type O vs. all other heart 
transplants (solid line: donor ABO type O, dashed line: all other donor types). A table 
is given with the number of patients at risk at each time point. The p-value corresponds 
to Mantel-Cox log-rank test results. 
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Figure 4. Kaplan-Meier graft survival analysis, donor type B vs. donor type O heart 
transplants (solid line: donor ABO type B, dashed line: donor ABO type O). A table is 
given with the number of patients at risk at each time point. The p-value corresponds to 
Mantel-Cox log-rank test results. 
 
DISCUSSION 
Since the advent of cardiac transplantation in the 1960’s, physicians have made 
considerable efforts to improve short and long-term transplant outcomes by investigating 
the causes of graft rejection and generalized graft failure. Immunologically, as with other 
transplanted organs, this has involved minimizing antigenic mismatches between graft 
donors and recipients. Due to the high demand and comparatively low supply of available 
organs for transplant, emphasis has also been placed on generating graft allocation 
policies that are fair and effective. Due to the multifactorial nature of graft failure, these 
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efforts have led to a debate as to the impact of ABO blood type compatibility as well as 
the importance of HLA-matching on adult heart transplant outcomes.  
 In terms of HLA-matching, Opelz and colleagues definitively showed a strong 
relationship between donor-recipient HLA-A, -B, and –DR mismatches on post-
transplant graft survival through the collaborative transplant study [28]. More recent 
studies have demonstrated that the presence of circulating HLA-directed donor-specific 
alloantibodies is correlated with increased morbidity and mortality, cardiac allograft 
vasculopathy, and increased rates of graft rejection [29,30]. 
With regards to ABO blood type matching, initial reports suggested that ABO 
compatible transplants are less efficacious than ABO identical ones [23,24]. More 
recently, investigators have disagreed with this conclusion [25,26,31]. A common 
problem of past studies has been a relatively small sample size precluding strong 
statistical power. In our analysis, we demonstrated that ABO identical and ABO 
compatible heart transplants have similar outcomes in terms of graft survival. By 
analyzing all adult cardiac transplants performed between 2000 and 2010, we were able 
to utilize a modern cohort of patients with a significantly larger sample size. Although 
our univariate analysis did show statistically significant differences in survival at 30 days, 
1 year, 3 years, and 5 years post-transplant between the two study cohorts, these 
differences did not hold up after controlling for potential confounding variables in the 
multivariable models. 
One of these possible confounding variables was OPTN waitlist status at 
transplant. Interestingly, according to our analysis ABO compatible heart recipients were 
more often status 1A at transplant when compared with ABO identical recipients (50.3% 
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vs. 37.8%). Additionally, ABO compatible recipients were more likely to be in the ICU 
as well as on a number of different mechanisms of life support including ECMO, IABP, 
parenteral inotropes, and ventilator support, than ABO identical heart recipients. This 
data suggests that ABO compatible recipients are generally sicker than ABO identical 
recipients, contributing to a worse prognosis. This is further supported by the fact that 
ABO compatible recipients had a higher pre-transplant mean total bilirubin compared 
with ABO identical recipients (1.48 vs. 1.25 mg/dL) indicating a greater degree of heart 
failure.  
On analysis of recipient cause of death by ABO blood type matching, ABO 
compatible recipients died as a result of primary graft failure more frequently than 
recipients of ABO identical hearts (8.7% vs. 5.8%). Heart transplant recipient mortality 
due to primary graft failure is frequently associated with “marginal” donors or recipients 
[32]. This seems to suggest that ABO compatible transplants involve more “marginal” 
recipients and/or donors than ABO identical transplants.  
In multivariate analysis, ABO blood type matching (identical vs. compatible) was 
not a statistically significant predictor of decreased cumulative or 30-day graft survival. 
Instead, the Cox proportional hazards model indicated recipient ethnicity (specifically, 
African American), life support at transplant (ventilator support and ECMO), graft 
ischemic time, total bilirubin, and recipient status before transplant to be significant 
predictors of decreased graft survival post-transplant. The multivariate logistic regression 
model indicated many of these variables – life support at transplant, ischemic time, 
bilirubin, and status before transplant, as well as waitlist status as statistically significant 
predictors of graft failure within 30 days of transplant. Other studies have demonstrated 
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similar results with regards to risk factors for decreased survival and increased graft 
failure following heart transplants [33-35]. 
The observed discrepancies in the effect of ABO compatibility on cardiac 
transplant outcomes between our univariate and multivariate models can be explained by 
investigating the impact of individual donor ABO blood types on graft survival. As we 
discovered in both our univariate and multivariate analyses, donor ABO blood type O is 
associated with decreased graft survival when compared with all other types. Since blood 
type O donor grafts are transplanted into recipients of all blood types (Table 1), the 
poorer outcomes associated with type O donor hearts could be skewing the results of our 
univariate analysis to misleadingly suggest that ABO compatible transplants result in 
worse outcomes than ABO identical ones. We confirmed this hypothesis by removing all 
type O donors from our univariate analysis, which demonstrated no statistically 
significant difference in graft survival at all time points post-transplant between ABO 
identical and compatible cohorts (p > 0.05). 
The poor outcomes associated with type O donor grafts do have implications for 
current organ allocation policies. According to the Organ Procurement and 
Transplantation Network (OPTN) policy 3.7.8.1 from February 2013, “Blood type O 
donors shall only be allocated to blood type O or blood type B patients” before being 
offered to blood type A or AB patients. Given the relatively poorer outcomes associated 
with blood type O grafts in type B recipients, this policy may need to be reviewed. Any 
future modification of the current organ allocation scheme must take into account the 
ABO blood type demographics within the United States, however. Therefore, limiting 
type B recipients to type B donor grafts for example might do more harm than good. 
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Interestingly, previous studies have shown that blood type O individuals experience 
decreased rates of morbidity with regards to conditions such as congestive heart failure 
[36]. Further research should be conducted to investigate possible explanations for the 
poor outcomes associated with blood type O donor hearts as well as the best organ 
allocation scheme for managing these grafts.  
 
CONCLUSION 
In the past decade, ABO compatible donor hearts were preferentially given to 
sicker transplant recipients. As demonstrated in this study, transplantation using ABO 
compatible adult hearts does not result in adverse outcomes with respect to graft survival 
and incidence of acute rejection compared with ABO identical grafts. Therefore, ABO 
compatible and ABO identical heart transplant matches should be viewed equally in 
clinical decision-making and to maximize efficiency within the available donor pool. 
This will help optimize the use of donor organs, an extremely important yet scarce 
resource. In doing so, waiting times could be shortened and overall outcomes could be 
improved. In addition, since ABO blood type O donor grafts are associated with 
decreased survival post-transplant, current organ allocation policies should be reviewed; 
particularly those pertaining to ABO blood type B heart transplant recipients.  
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OVERALL CONCLUSIONS 
Through this retrospective cohort analysis of heart transplantation outcomes, we 
identified several potential mechanisms through which post-transplant survival could be 
improved. Before conducting the myocarditis analysis, we hypothesized that post-
transplantation survival would be quite dissimilar between recipients with a history of 
myocarditis and those with ischemic or idiopathic dilated cardiomyopathy. While the 
baseline characteristics of these two recipient cohorts were indeed quite different, we 
were surprised to discover that post-transplantation survival was in fact similar, although 
recipient cause of death varied. With respect to our ABO analysis, we initially 
hypothesized that ABO identical and ABO compatible transplants would be associated 
with identical survival curves. We were once again surprised to discover that certain 
ABO compatible blood type pairings were actually associated with poorer outcomes. 
While further investigation is certainly warranted, these results suggest that post-heart 
transplantation survival might be improved with more intensive immunosuppression 
regimens for myocarditis patients and alterations in the current UNOS organ allocation 
policy for ABO compatible matches.   
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LIMITATIONS 
Like any other retrospective cohort study, this investigation was limited by the 
strength of the primary database in terms of completeness, accuracy, quality, and 
appropriateness of the predictor variables. While the dataset provided by UNOS was 
extremely comprehensive and included many important variables that described baseline 
donor and recipient information as well as post-operative outcomes, the study could have 
been strengthened if additional data were available to us. Furthermore, as it is a large 
national database compiled over many years, the accuracy of all the patient information 
coded in the UNOS database cannot be guaranteed. We are confident, however, that 
given the nature of our investigation, an analysis of a large national cohort of patients, 
any errors in patient data will not bias our results.  
An additional limitation of the study is a result of analyzing many years of data. 
In order to accumulate enough patient records, in the case of the myocarditis analysis, 
several decades of patient data was required. During this prolonged period, many 
advances were made with regard to transplantation techniques, organ allocation policies, 
and immunosuppression regimens. These advances might have introduced biases into the 
study, impacting the results. 
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